ASX - By Stock
|
NEU |
Re:
Ann: P2 trial shows significant improvements in Phelan-McDermid
|
|
bclb
|
210 |
91K |
2 |
19/12/23 |
19/12/23 |
ASX - By Stock
|
210
|
91K
|
2
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
bclb
|
11K |
5.2M |
12 |
23/09/23 |
23/09/23 |
ASX - By Stock
|
11K
|
5.2M
|
12
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
bclb
|
11K |
5.2M |
22 |
23/09/23 |
23/09/23 |
ASX - By Stock
|
11K
|
5.2M
|
22
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
bclb
|
11K |
5.2M |
18 |
27/03/23 |
27/03/23 |
ASX - By Stock
|
11K
|
5.2M
|
18
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
bclb
|
11K |
5.2M |
0 |
16/03/23 |
16/03/23 |
ASX - By Stock
|
11K
|
5.2M
|
0
|
|
ASX - By Stock
|
NEU |
Re:
Updated Broker/Analyst targets, first one at $18.29
|
|
bclb
|
37 |
15K |
5 |
16/03/23 |
16/03/23 |
ASX - By Stock
|
37
|
15K
|
5
|
|
ASX - By Stock
|
NEU |
Re:
FDA Approval
|
|
bclb
|
116 |
52K |
1 |
12/03/23 |
12/03/23 |
ASX - By Stock
|
116
|
52K
|
1
|
|
ASX - By Stock
|
NEU |
Re:
Share Price
|
|
bclb
|
11K |
5.2M |
12 |
08/12/21 |
08/12/21 |
ASX - By Stock
|
11K
|
5.2M
|
12
|
|
ASX - By Stock
|
NEU |
Re:
BIOGEN ALZHEIMER APPROVED
|
|
bclb
|
5 |
2.7K |
1 |
09/06/21 |
09/06/21 |
ASX - By Stock
|
5
|
2.7K
|
1
|
|
ASX - By Stock
|
NEU |
Re:
Who is keeping the price down .
|
|
bclb
|
103 |
54K |
1 |
26/05/21 |
26/05/21 |
ASX - By Stock
|
103
|
54K
|
1
|
|
ASX - By Stock
|
NEU |
Re:
Ann: Neuren to capture substantially greater value after Phase 3
|
|
bclb
|
96 |
37K |
0 |
17/03/20 |
17/03/20 |
ASX - By Stock
|
96
|
37K
|
0
|
|
ASX - By Stock
|
NEU |
Re:
Below benchmark for 1st month
|
|
bclb
|
48 |
22K |
33 |
02/08/17 |
02/08/17 |
ASX - By Stock
|
48
|
22K
|
33
|
|